Neuron to Publish PBT2 preclinical research

Press Release: Prana Biotechnology Neuron to Publish Prana’s PBT2 preclinical research - Significant cognitive benefits and reduction in Abeta demonstrates disease modification benefits - Full data to be presented at ICAD in Chicago on July 29, 2008 Melbourne, Australia – July 10, 2008 –Prana Biotechnology Ltd. (OTC: PRNAF, ASX: PBT) announced the publication of key research findings with its lead Alzheimer’s Disease drug, PBT2. The article titled “Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxyquinoline analogs" is associated with decreased interstitial Abeta” appears in the current edition of the prestigious scientific journal Neuron, and can be viewed online. The key findings reported are: - PBT2 profoundly and rapidly improved cognition in transgenic mice. - PBT2 prevented the formation of... [read full story]